
- Article published at:
- Article author: Shahram Lavasani
- Article comments count: 0
Drawer menu
Dagens Nyheter, one of Sweden’s most prominent newspapers, published an article under its Health section titled:
“A More Successful Healthcare with ImmuneBiotech’s Precision Probiotics.”
The article spotlights us at ImmuneBiotech, highlighting our growing role in the future of health care, our pioneering work in Precision Probiotics, and the cutting-edge science behind our product development. We are incredibly proud that our flagship product, GutMagnific, has garnered not only national recognition but also strong international interest.
Researchers and clinicians around the world are paying increasing attention to the connection between gut dysbiosis — an imbalance in the microbial ecosystem — and chronic conditions ranging from digestive disorders to neurological diseases.
Dagens Nyheter’s article showcases how ImmuneBiotech is leading the way in developing targeted, science-based solutions that address these underlying root causes.
At ImmuneBiotech, our mission has always been to develop products with patient-centric precision. Our first product, GutMagnific, is a unique Precision Probiotic formulated to:
✅ Restore balance in the gut microbiota
✅ Support a healthy immune response
✅ Normalize gut permeability and strengthen the gut barrier
The article also reflects the growing international demand for innovative, research-backed solutions like GutMagnific — a clear sign that Precision Probiotics are the future of personalized gut health support.
What sets ImmuneBiotech apart is our deep scientific expertise and commitment to innovation. With over 20 years of research in immunology, microbiology, and medical science, our team continues to explore how precision-formulated probiotics can support not only digestive health but also overall well-being.
We are incredibly proud to be recognised by Dagens Nyheter and it strengthens our passion to continue delivering scientifically grounded, high-quality health solutions.